Skip to main content
main-content

18.12.2017 | Original Paper

Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens–Johnson syndrome

Zeitschrift:
International Ophthalmology
Autoren:
Hyeon Jeong Yoon, Mee Kum Kim, Kyung Yul Seo, Mayumi Ueta, Kyung Chul Yoon

Abstract

Purpose

To investigate the effectiveness of combined photodynamic therapy with verteporfin and intrastromal injection of bevacizumab for the treatment of corneal neovascularization in patients with Stevens–Johnson syndrome (SJS).

Methods

Eight eyes of eight patients with SJS having corneal neovascularization who were refractory to 1% prednisolone instillation received photodynamic therapy with verteporfin (6 mg/m2) combined with intrastromal bevacizumab injection (2.5 mg/0.1 mL). Best-corrected visual acuity and intraocular pressure were assessed, and slit-lamp biomicroscopic examination was performed before treatment and at 1 week and every month. A chronic ocular manifestation score was assigned based on the involvement area or the severity before treatment. The cumulative length of corneal blood vessels and area of corneal neovascularization were measured by anterior segment photographs before and after treatment.

Results

At 3 and 6 months after treatment, all eyes showed regression of corneal neovascularization. Complete regression was achieved in five eyes (62.5%) and partial regression in three eyes (37.5%). Among five patients who were followed up for more than 1 year, two eyes maintained complete regression and one eye maintained partial regression at 1 year. However, two eyes with severe chronic ocular manifestation showed revascularization.

Conclusions

Combined photodynamic therapy with intrastromal bevacizumab injection can effectively inhibit corneal neovascularization in patients with SJS. However, patients with severe chronic ocular manifestation may exhibit revascularization.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Literatur
Über diesen Artikel

Neu im Fachgebiet Augenheilkunde

06.07.2018 | Leitlinien, Stellungnahmen und Empfehlungen | Ausgabe 8/2018

Empfehlungen der DOG für die Planung klinischer Studien im Auftrage Dritter

März 2018

29.06.2018 | Das therapeutische und diagnostische Prinzip | Ausgabe 8/2018

Neuer Glaskörperersatz mit Hydrogel?

15.06.2018 | Video plus | Ausgabe 7/2018

Diakaustische Kammerwinkeluntersuchung

Videobeitrag